Fairvalue-Calculator Fairvalue-Calculator
EN DE

Protalix BioTherapeutics, Inc (PLX) Fair Value & Analysis

Healthcare · US · Market cap $179M

Price$2.17
Fair Value$2.69
Upside+24.0%
Quality95/100
Evidence: Low Range $2.02 – $3.37

Fair value as of: Jun 24, 2026

Analysis

Protalix BioTherapeutics, Inc (PLX) currently trades at $2.17, while our model-based Fair Value estimate is $2.69 — implying the stock looks roughly 24.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Protalix BioTherapeutics, Inc (PLX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $2.69 versus a price of $2.17 — about +24% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PLX?
Our 21-model fair value for Protalix BioTherapeutics, Inc is $2.69 (as of Jun 24, 2026), built from audited fundamentals. The current price is $2.17.
What is the quality score of PLX?
Protalix BioTherapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.